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1. Introduction 
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder, its 
prevalence is increasing along with population longevity and there is no cure for this 
disease so far, despite of the amount of information research has provided. This leads us to 
seek for better treatments able to improve the patient’s and caregivers’ quality of life. In this 
chapter we will review some of the main aspects of those proteins playing a key role in the 
pathological processes of Alzheimer’s disease, as well as the therapeutic strategies currently 
in use and those that have been developing in the last few years for the treatment of this 
disease.  
We will take a look on the processes of formation of the characteristic lesions of the 
Alzheimer’s brain and sum up some of the properties of the main proteins involved in such 
processes leading to neuronal damage and death and the resulting cognitive decline. We 
will also have an overview of the current drugs of choice for Alzheimer’s treatment and 
discuss about the latest therapies research has been developing to treat AD in its different 
stages, such as a therapy of our own proposal for the repair of neuronal membranes prior to 
initiate a conventional drug treatment and the advantages these strategies would provide 
combined on patients with a mild to moderate neuronal damage. At last we will focus on 
the importance of an integral care of Alzheimer’s patients. 
2. A quick view into the Alzheimer’s brain 
Two characteristic lesions develop within the brain of an AD patient, namely neuritic 
plaques and neurofibrillary tangles, both responsible for the symptomatology due to 
neuronal damage and death. We will take now a short look into these lesions. 
2.1 Neuritic plaques 
The so called neuritic or amyloid plaques are mainly extracellular aggregates of insoluble 
filaments of β-amyloid peptides with adjacent microglia, frequently surrounded by 
astrocytes. The dystrophic neurites are located into and around these amyloid deposits. 
Plaques are largely found in the limbic and association cortices, where they slowly start to 
develop over the years preceding the onset of the disease. 
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2.1.1 β-amyloid formation 
β-amyloid peptides (Aβ) are the result of the sequential actions of the secretases over the 
amyloid precursor protein (APP). When APP is cleaved by the β- and γ-secretases the 
insoluble amyloid species are released (Figure 1). Some authors suggest a physiological role 
for Aβ in memory processes and as a regulator of the potassium channels expression and 
neuronal excitability (Ohno et al., 2004; Plant et al., 2006). 
2.1.2 The amyloid precursor protein 
APP is a type I membrane protein member of a small family with a large extracellular 
domain and a short cytoplasmic one, APP presents three main isoforms (695, 751 and 770 
residues) and is the only protein containing the Aβ sequence. The 695 residues is the most 
abundant isoform in neurons, but other brain cells also express variable amounts of APP 
and non-neural cells express mainly the 751 and 770 residues APP isoforms. The APP gene 
is located in chromosome 21 and over 25 mutations to this gene have been described as 
responsible for familial forms of AD (Thinakaran & Koo, 2008; Hung & Selkoe, 1994; Haas et 
al., 1991). APP undergoes a variety of post-translational modifications and proteolitic 
cleavages along and after its pass through the secretory pathway, releasing its derivatives 
into the lumen of secretory vesicles and the extracellular space (Selkoe, 2001). This protein 
has a poorly understood physiological role, but there have been autocrine and paracrine 
growth functions as well as trophic functions described, it is involved in neurite growth and 
synaptogenesis (Hung et al., 1992; Muresan et al., 2009; Chan et al., 2002).  
2.1.3 The secretases 
The α-, β- and γ-secretases cleave APP in several sites generating soluble peptides and 
membrane fragments as well as the insoluble Aβ peptides (Aβ40 and Aβ42) of amyloid 
plaques, these last as a result of the sequential actions of β-secretase (beta-site APP cleaving 
enzyme-1, BACE1) and the γ-secretase complex (composed by the presenilines-PS1 or PS2-, 
APH-1, PEN-2 and nicastrin).  
The β-secretase gene is localized in chromosome 11 and it responds to stress conditions. 
Almost every tissue expresses BACE1, nevertheless its highest levels of expression are found 
in the brain. This enzyme has a 501 amino acids sequence containing two aspartil protease 
active sites and is located within cholesterol rich lipid rafts; it is believed BACE1 plays a role 
in synaptic function and the myelination process (Riddell et al., 2001; Ma et al., 2007; Cole & 
Vassar, 2007). On the other hand, γ-secretase is an enzymatic complex formed by four 
essential protein subunits necessary for an active mature complex. Mutations in either of the 
two preseniline genes (PS1, chromosome 14 and PS2, chromosome 1) have been described in 
cases of familial AD (Yu et al., 2000; Thinakaran & Koo, 2008). This secretase cleaves APP in 
several sites within its transmembrane domain perhaps to regulate programmed cell death, 
there is some evidence supporting a relationship between APP and PS expression levels and 
apoptotic activity (Vito et al., 1996). 
2.2 Neurofibrillary tangles 
These lesions are mainly the result of the intracellular aggregation of hyperphosphorylated 
protein tau in the form of paired helical filaments (PHFs) in the brain regions affected by 
AD, such as the enthorrinal cortex, hippocampus, parahippocampal gyrus, amygdala and 
frontal, temporal, parietal and occipital association cortices and subcortical nuclei projecting 
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to these regions (Brion et al., 1985; Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina & 
Ihara, 1986; Wood et al., 1986).  
 
 
Fig. 1. Processes of formation of neuritic plaques and neurofibrillary tangles 
Microtubule-associated protein tau (MAPT) promotes the microtubule assembly and 
stabilization required for morphogenesis and axonal transport in neurons, but it is also 
found in other cell lines (Johnson & Hartigan, 1999; Ingelson et al., 1996; Thurston et al., 
1996). Tau gene is localized in chromosome 17. This protein controls microtubule stability in 
two ways: isoforms and phosphorylation. Tau phosphorylation in several sites regulates in a 
negative manner the protein’s ability to bind to microtubules (Pope et al., 1994; Preuss et al., 
1995; Preuss & Mandelkow, 1998; Illenberger et al., 1998), being this one the reason why the 
hyperphosphorylation of tau is a crucial event in the pathophysiology of AD. When tau gets 
hyperphosphorylated, it dissociates from microtubules and forms the PHFs which aggregate 
in the perinucleic cytoplasm, leaving a destabilized membrane to deform and lose synaptic 
activity (Figure 1).  While neuritic plaques are thought to develop in a minor amount within 
the normal aging brain, the hyperphosphorylation of tau is almost an exclusive event of AD 
and the so called tauophaties. 
3. The Alzheimer’s therapeutic strategies 
As we shall remember there is no cure for AD, however drug treatments are available to 
help with the symptomatology in several aspects of the disease and researchers keep 
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making efforts around the world to find better treatments as well as preventive strategies 
and ultimately a cure for AD.  
3.1 Available drug treatments 
Now we will review some of the characteristics of those drugs most widely used and 
approved by the Food and Drug Administration (FDA) for the treatment of AD, these are 
mainly divided into two groups: the acetylcholinesterase inhibitors and the NMDA receptor 
antagonists (this last represented by Memantine). We should consider here that these drugs 
are designed to diminish the symptoms originated by the neurodegeneration but that 
neither of them targets the plaques and/or tangles to destroy them or to stop the processes 
responsible for their formation and progress; they provide cognitive improvement by 
different means. It is also convenient here to say that these are not the only drugs that have 
shown beneficial effects on AD patients, nevertheless no other drug has been approved for 
AD treatment so far.  
3.1.1 Acetylcholinesterase inhibitors 
Diminished cholinergic function is a normal feature in aging, in AD and other dementias it 
becomes of special severity however. The physiological processes underlying AD’s 
pathology cause a decline in acetylcholine levels, exacerbated by the neurotransmitter’s 
degrading enzyme, the acetylcholinesterase. The members of this group support 
communication between nerve cells by increasing the acetylcholine levels and availability at 
the synaptic cleft (Figure 2), they suppress acetylcholinesterase to prevent acetylcholine 
degradation.  
 
 
Fig. 2. Action mechanism of acetylcolinesterase inhibitors 
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There are three types of acetylcholinesterase inhibitors: short-acting, medium-duration and 
irreversible inhibitors; the difference between each other is the way they interact with the 
active site of the enzyme (Rang et al., 2001). The general side effects of these drugs may 
include diarrhea, nausea, dizziness, fatigue, loss of appetite and insomnia; the treatment 
with any of them should be monitored and start with low initial doses progressively 
increased until the maximum recommended daily dosage is reached. Precautions must be 
taken with concomitant (cardiovascular, gastrointestinal, pulmonary, urinary, neurological) 
diseases (De la Vega-Cotarelo & Zambrano-Toribio, 2011). 
A. Tacrine (Cognex) 
Derived from acridine, tacrine was one of the first drugs developed to help with the main 
symptoms of AD such as memory problems, cognitive decline and behavioral changes. 
Tacrine has been approved for the treatment of mild-to-moderate AD. Besides its 
acetylcholinesterase inhibiting activity, tacrine may also act as a potassium channel blocker 
which would increase the release of acetylcholine by functional cholinergic neurons. It 
should be noticed that tacrine has been associated with increased levels of transaminases 
(40-50% of patients) although its damage mechanism and efficacy remain controversial. This 
drug is contraindicated in conditions including cardiovascular disease, asthma, 
hyperthyroidism, urinary obstruction, prostatic hypertrophy, peptic ulcer and hepatic 
disease. The treatment with tacrine initiates with 10 mg/6h for at least 6 weeks and 
progressively increases every 6 weeks until a 30 mg/6h dosage; this treatment must be 
monitored for drug interactions, liver toxicity, severe side effects and efficacy to identify the 
need for interruption due to highly adverse conditions induced by tacrine administration.  
B. Galantamine (Razadyne) 
It is a natural compound derived from Galanthus nivalis. Galantamine directly stimulates 
nicotinic receptors to acetylcholine (which are especially important for learning and short-
term memory processes) allosterically, avoiding receptor desensitization and down-
regulation, although these receptors are damaged in AD. The main characteristics of 
galantamine are the protective role it has shown in cortical neurons, preventing these cells 
from the cytotoxicity of the amyloid peptides and from suffering oxidative stress, and the 
inhibition of Aβ aggregation; besides, galantamine increases acetylcholine release and 
modulates the levels of other neurotransmitters such as GABA, serotonin and glutamate. 
Galantamine is approved for mild-to-moderate stages of the disease. Its administration 
depends on the pharmaceutical presentation but usually dose does not exceed 24 mg/day 
with a regular evaluation of side effects and clinical benefit. 
C. Donepezil (Aricept) 
This drug is a piperidine derivative, being a reversible acetylcholinesterase inhibitor with 
good specificity it shows few side effects, there is no risk for hepatotoxicity with this drug. 
Donepezil has been approved for moderate-to-severe AD with a maximum administration 
of 10 mg/day every night before going to bed.  
D. Rivastigmine (Exelon) 
It is a carbamate compound which, compared to donepezil, shows better tolerance by 
patients and fewer side effects; however, its effectiveness is more limited than that of 
donepezil and the main concern about its use is the possibility of severe gastric damage and 
hepatotoxicity after its prolonged consumption. Rivastigmine has been approved for mild-
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to-moderate AD in a low dosage (depending on the route of administration, until 12 
mg/day). This drug is also used to treat dementia linked to Parkinson’s disease.  
3.1.2 Memantine 
This non-competitive, voltage-dependent and of moderate affinity N-methyl-D-aspartate 
(NMDA) receptor antagonist regulates glutamate activity and prevents neuronal cells of an 
excessive income of calcium ions (Figure 3). Memantine (Namenda) is the only drug of its 
kind that has been approved by the FDA for the treatment of moderate-to-severe AD; its 
side effects may include hallucinations, confusion, dizziness, headaches and debilitation. 
Some authors have reported a decreasing activity for memantine of the amyloid peptide 
aggregation and prevention of synaptic dysfunction as well. Besides, it has been suggested 
by studies in transgenic mice inhibiting and reversing activities of the abnormal 
hyperphosphorylation of tau by a mechanism involving protein phosphatase-2A (Aronov et 
al., 2001).  
The treatment of AD with memantine, as with acetylcholinesterase inhibitors, requires low 
initial dosages (5 mg/day) which will be progressively increased depending on the patient’s 
tolerance until the maximum recommended is reached (20 mg/day), with constant 
monitoring of drug interaction, toxicity, efficacy and adverse side effects (Table 1). 
Memantine is contraindicated in cases of renal insufficiency, epilepsy, concomitant 
administration of amantadine, ketamine and dextromethorphan and conditions leading to 
an increase in urinary pH.  
3.1.3 Auxiliary drugs 
Symptoms of AD are often divided into cognitive, behavioral and psychiatric and thus exists 
a wide variety of symptoms accompanying the disease. Cognitive symptomatology affects 
memory, judgment, language, attention, planning and thinking processes while behavioral 
and psychiatric symptomatology affects the way a patient acts and feels and amongst these 
last are included anxiety, restlessness, hallucinations and delirium; besides there are other 
physical problems AD patients are prone to present and the side effects of primary drug 
treatments and drug interactions. For this reason it becomes of importance to attend the 
whole range of symptoms accompanying the disease.  
For psychiatric symptoms should always be tried first a non-pharmacologic therapy 
followed, if necessary, by a pharmacologic treatment. Treatable conditions include, as we 
mentioned before, side effects of the primary drugs and interactions between drugs, 
symptoms of some common diseases and vision and hearing problems. Medication must 
target specific symptoms to contribute to the control of behavioral changes due to anxiety 
and restlessness originated by the accompanying symptomatology of AD (Table 2). 
3.2 Developing therapies 
A wide variety of research groups around the globe focus their investigations on the 
discovery of new biomarkers that serve as tools for an early diagnosis of AD in order to 
make treatments more effective when applied at the very first stages of the disease, where 
neuronal loss is not that significant for patients to present marked cognitive decline and it 
could be still possible to delay the neurodegenerative process. Along with that, many 
research groups are making efforts to develop new therapies for the treatment of AD using 
pharmacologic and non-pharmacologic strategies. Our group is currently investigating both 
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Fig. 3. Action mechanism of memantine 
 
Group Drug AD stage Beneficial effect Risk Dosage 
Acetilcholinesterase 
inhibitor 
Tacrine Mild-to-
moderate 
Improves 
cognition and 
behavior 
Hepatotoxicity Initial: 10 mg/6h 
Maintenance: 30 
mg/6h 
 Galantamine Mild-to-
moderate 
Improves 
learning and 
memory, cor-tical 
protection, in-
hibition of Aβ 
aggregation 
Nausea, vomi-
ting, weight 
loss 
Solution- Initial: 4 
mg/12h 
Maintenance: 8 
mg/12h 
Capsules-Initial: 
8mg/day 
Maintenance: 16 
mg/day 
Maximum: 24 mg/day 
 Donepezil Moderate-to-
severe 
Improves 
cognition 
Good tolerance 
Muscle 
weakness 
Initial: 5 mg/day 
Maintenance: 10 
mg/day 
 Rivastigmine Mild-to-
moderate 
Improves 
cognition 
Good tolerance 
Gastric damage
Hepatotoxicity 
Oral-Initial: 1,5 
mg/12h 
Maintenance: 3-6 
mg/12h 
Transdermic-Initial: 
4,6 mg/day 
Maintenance: 9,5 
mg/day 
NMDA receptor 
antagonist 
Memantine Moderate-to-
severe 
Decreases Aβ 
aggregation, pre-
vents synaptic 
dys-function,  
inhibits tau 
hyperphospho-
rylation 
Hallucinations 
Confusion 
Debilitation 
Initial: 5 mg/day 
Maintenance: 20 
mg/day 
Table 1. Drugs approved for the AD treatment 
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the identification of gene expression-based peripheral biomarkers and the effectiveness of a 
neuronal rehabilitating therapy based mostly on natural products. 
 
Conditions to control Drugs Examples 
Humor, Irritability Antidepressants Citalopram, Fluoxetine, Paroxetine, 
Sertraline, Trazodone 
Anxiety, Verbal problems, 
Resistance, Restlessness 
Anxiolytics Loracepam, Oxacepam 
Hallucinations, Delirium, 
Aggression, Agitation, 
Hostility, Lack of cooperation 
Antipsychotics Aripiprazole, Clozapine, 
Haloperidol, Olanzapine, Ketiapine, 
Risperidone, Ziprasidone 
Table 2. Auxiliary drugs in the treatment of AD’s symptomatology 
There has been studied the possibility of using anti-inflammatory drugs in the treatment of 
AD due to the evidence on the importance of inflammatory processes in the 
pathophysiology of AD. We shall notice two aspects in this subject: the presence of immune 
response in the AD brain and the immune response originated peripherally in these 
patients. Neuro-inflammation is a silent process occurring with morphological changes in 
activated microglia, the generation of reactive oxygen species (ROS) and other toxic 
materials, complement activation and cytokine release (Rogers et al., 1996; P.L. McGeer & 
E.G. McGeer, 1999, 2002); it is suggested that this inflammatory process might be due to the 
amyloid aggregation and damage to the blood brain barrier (BBB) (Hickey, 2001). The stress-
induced production of pro-inflammatory cytokines and stress hormones by lymphocytes 
associates with several age-related diseases. In the AD, these peripheral processes may 
enhance the amyloid-induced inflammation in the brain. Because all of these, non-steroidal 
anti-inflammatory drugs (NSAIDs) (Anthony et al., 2000) and berberine (Zhu et al., 2006) 
have been investigated with therapeutic purposes for AD. 
Immunotherapeutic approaches seek for the induction of an immune response against 
amyloid deposits. Three modalities are distinguished: passive immunization, active 
immunization and genetic vaccination; the last meaning the transfection of genes which 
produce the antigen. Immunization has proven efficient in animal models of AD, with 
several epitopes presenting different immunological properties being tested, as well as the 
mechanisms by which they exert an effect on Aβ clearance (Menéndez-González et al., 
2005). Although clinical trials have failed so far, they rendered some relevant observations 
for the improvement of these strategies.  
Other therapeutic strategies in development involve several methods to restore lipid 
homeostasis, promote synaptogenesis and regeneration and reduce Aβ production in the 
AD brain based on ApoE manipulation (Cedazo-Mínguez et al., 2007). Also, an increase in 
insulin stimuli in the brain could help improve memory in AD patients (Benedict et al., 
2007). Nerve growth factor (NGF) and insulin-like growth factor-1 have shown a reduction 
of cognitive impairment and improvement of neurological functions in models of AD 
(Alzheimer’s Research Center, 2008). Antioxidants, ginkgo biloba, estrogens and omega-3 
fatty acids, among some other natural products, have also been investigated for therapeutic 
effects on AD. Despite the promising results of several of these studies, there still is a long 
way to go until some of these strategies could be available for the general population; 
nevertheless, each and every day we could be a step closer to develop a really effective 
treatment for such a complex disease as AD. 
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3.2.1 Neuro-rehabilitation in Mild-to-Moderate AD stages 
AD treatment with both acetylcholinesterase inhibitors and Memantine has a quite reduced 
period of about six months of true effectiveness and noticeable results in patients, probably 
because of two reasons. Neither of these drugs is designed to stop the pathophysiological 
processes occurring within the AD brain, thus in one hand neurons keep degenerating and 
lesions growing in a slowly but progressive manner and synaptic connections are 
interrupted; on the other hand, the plasma membrane of neural cells is suffering a loss in 
stability and shape what we believe leads to the misplacement of receptors at the cell 
surface, leaving them unreachable for the neurotransmitter binding or even that both the 
neurotransmitter cannot be released and its receptor might not be properly carried to the 
cell surface because of the resulting damaged anterograde and retrograde transports. Thus 
despite of the neurotransmitter’s maintained availability at the synaptic cleft, it is not able to 
reach the postsynaptic neuron and bind to its receptor or even the amount of 
neurotransmitter released from the presynaptic neuron is not enough to generate an 
adequate action in the postsynaptic neuron (Figure 4).  
 
 
Fig. 4. Drugs do not function because of the damaged membrane 
Because of all the above, our group proposed an alternative therapy for AD focused on 
neuronal membrane repair what would restore its functionality, including the transport of 
molecules such as neurotransmitters and their receptors, the availability of receptors 
binding domains and the correct placing of membrane molecules (receptors, enzymes and 
carriers). This therapy is based on a daily consumption of natural products including 
omega-3 and folic acids, ginkgo biloba and resveratrol which cause no side effects and have 
shown to provide good advantages for neuronal functionality, in addition of their easy 
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accessibility. We also include Nimesulide for the inflammatory component of AD, and 
Fluoxetine or Escitalopram to promote neuronal reconnection. We suggest that a 
rehabilitation of neuronal membranes followed by or combined with the conventional drug 
treatments (Table 3) would enhance and prolong the beneficial effects of the treatment in 
AD patients. This therapy has shown good results so far (Aranda-Abreu et al., 2011) and 
there are currently more subjects initiating the protocol to test this therapy including 
normally aged individuals, AD patients and patients suffering from neurological disorders 
and dementias different from AD.  
 
Omega-3 600 – 1000 mg (Membrane repair) 
Resveratrol 60 mg (Antioxidant) 
Ginkgo biloba 60 mg (Memory processes) 
Day 
Escitalopram 10 mg (Neuronal reconnection) 
Folic acid 1 mg (Neuronal integrity maintenance) 
Night 
Nimesulide 100 mg (Anti-inflammatory – If necessary) 
Alzheimer’s drug treatment as medical doctor indicated 
Table 3. The Neuro-rehabilitation therapy recipe* 
The neuro-rehabilitation therapy involves four aspects: 
A. Neuronal membrane restoration. 
B. Maintenance of neuronal integrity. 
C. Neuronal reconnection. 
D. Activation of memory processes. 
A. Neuronal membrane restoration 
Omega-3 fatty acids, such as docosahexaenoic acid (DHA), are involved in neurite 
development, the remodeling of membrane lipid rafts and neurogenesis, and they have 
shown a reduction in the hyperphosphorilation of tau and amyloid aggregation in AD. 
Cholesterol rich lipid rafts associate with the stabilization and proper clustering of 
membrane receptors. Because of this, we use omega-3 fatty acids to repair the damaged 
neuronal membranes in order to restore the correct positioning and trafficking of membrane 
molecules, such as neurotransmitters and their receptors; this would help to stabilize the 
synaptic activity (Figure 5) and thus improve cognitive functioning.  
B. Maintenance of neuronal integrity 
The integrity of neuronal membranes should be maintained in both the remaining healthy 
neurons and those already restored. This is important because we shall remember here that 
we are not making the damaging processes to stop and thus membranes would tend to 
degenerate if we do not help to delay these processes. With this purpose we included folic 
acid in the neuro-rehabilitation therapy as it plays an important role in neuroplasticity and 
the maintenance of neuronal integrity by a mechanism involving one-carbon metabolism, 
which associates with neurological and psychiatric pathologies when deranged.  
                                                 
* From Aranda-Abreu et al., 2011, Dovepress. 
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Fig. 5. Membrane restoration by the remodeling of lipid rafts 
Resveratrol is also included in this therapy with the purpose of maintaining neuronal 
integrity. Resveratrol belongs to a group of molecules known as phytophenols, which act as 
free radical scavengers. Resveratrol is found in grape extracts and its use as antioxidant has 
become very popular nowadays because it protects against ROS toxicity and provides 
beneficial effects on inflammatory and neoplastic processes. In addition, resveratrol has 
shown a protective effect against Aβ toxicity in neuronal cell lines. The protection resveratrol 
provides to neuronal cells makes it a good agent to guard the integrity of these cells. 
C. Neuronal reconnection 
Neurons should be capable of making new connections between each other to re-establish 
cognitive processes. Some drugs such as Fluoxetine (Wang et al., 2008) and Escitalopram 
(Alboni et al., (2010) could help in this task by the induction of serotonin reuptake. Serotonin 
regulates neuronal morphology and its recapture is involved in the formation of new 
synapses, which would reconnect newly restored neurons (Figure 6). With their membranes 
repaired neurons regain the ability to receive and transmit impulses, thus once they make 
new inter-neuronal connections, the damaged AD brain would improve its functionality 
and cognitive impairment might be diminished. 
D. Activation of memory processes 
Ginkgo biloba is known for its beneficial effects on memory processes as well as its 
antioxidant activity. Among the pharmacological effects of ginkgo biloba are its antagonism 
to the platelet activation factor and the increase in GABA levels, glutamic decarboxylase and 
muscarinic receptors. Although consumption of ginkgo biloba with a therapeutic purpose 
for AD patients has brought inconclusive results, numerous authors report an improvement 
of the cognitive impairment in AD patients by the treatment with ginkgo biloba and we 
have observed good results in these patients after a follow up of one year from initiation of 
our neuro-rehabilitation therapy, which includes ginkgo. 
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Despite of the effects of ginkgo biloba on memory, we shall bear in mind that brain 
stimulation helps to keep it healthy. In AD, as in other neurodegenerative disorders, 
cognitive stimulation becomes of great importance for the rehabilitation process, improving 
memory and cognitive impairment. We will point out later the importance of stimulating 
the brain, along with other aspects, in order to assure the best possible outcome with this or 
any other AD treatment chosen. 
 
 
Fig. 6. Neuronal reconnections by serotonin recapture 
3.2.2 Stem cells and advanced AD 
Nowadays we have all heard about new therapies for all kinds of pathologies based on stem 
cells and AD is not the exception. In fact, the therapeutic strategy most widely investigated 
and, probably, promising for the severe cases of AD involves the growingly popular stem 
cells.  
As we know, in AD there is a progressive loss of neuronal cells and thus in advanced stages 
of the disease the loss in brain mass is very significant, reason why no other 
pharmacological treatment or non-pharmacological therapy could promise much of an 
improvement. At this point, the alternative would be to replace the already lost neurons 
with new ones of the same type, the last being the main problem encountered by researchers 
in this area. As some groups have been able to successfully proliferate and differentiate stem 
cells from different sources into neurons of several types in culture, they found this to be 
difficult to reproduce into the brain. The conditions required in vivo for stem cells to 
differentiate into specific lineages are yet to be unraveled and only then effective and 
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reproducible protocols could be developed to produce healthy and functional 
stem/progenitor cell-derived neurons (Wicklund et al., 2010). But even if we are to 
accomplish this task effectively another concern shall rise: would these cells be also affected 
by the disease in time? And, if so, how long would they provide an actual improvement on 
cognition before facing the pathophysiological processes of AD? 
In AD, a stem cell-based approach should be able to replace several types of neuronal cells 
in different brain regions (Figure 7) and show a significant rescue of cognitive functions, 
some studies in animal models have suggested an improvement of cognition by means of a 
variety of mechanisms different to the direct alteration of either tau or Aβ pathologies 
(Blurton-Jones et al., 2009).  
Another path to be taken would consist of protocols developed for endogenous stem cells 
stimulation. The main issue on this matter is the prevalent controversy about discrepant 
results on the effects of Aβ over stem cells and neurogenesis, as some studies suggest a 
neurogenic effect while others show neurotoxicity on stem/progenitor cells. Hence, 
modulation of the microenvironment within the AD brain would be crucial for the 
feasibility of this and other related approaches (Wicklund et al., 2010).  
 
 
Fig. 7. Stem cell transplantation into the AD brain 
4. Integral care of AD patients 
There are many aspects we should keep an eye on once an individual is diagnosed with AD, 
for such a complex disease must be attacked in all possible directions; as there is no magic 
treatment for AD one could use all the help one can possibly get (Table 4). In our present 
study we are instructing the caregivers of our patients on the best way to assure an integral 
care able to render the best outcome for the therapy as it is not enough to repair the 
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damaged neuronal membranes, to seek for neurogenesis, cognitive stimulation and the 
maintenance of neuronal functionality actually is the best way to enhance and prolong the 
positive effects of any AD therapy.  
 
 Characteristics Recommendations 
Nutrition Required for brain 
metabolism and synap-
tic function. 
HAD, EPA, vitamins (E, K, C, B6, 
B12), minerals (iron, iodine, 
manganese, copper, zinc), 
unsaturated fatty acids, fish, 5 small 
meals. 
Sleep Helps neurogenesis, 
neuronal plasticity, 
learning and memory 
No daytime naps, full 8 hr nighttime 
sleep, watch for sleep apnea, same 
bedtime every day. 
Physical exercise Good for metabolism, 
inflammation,  me-
mory, learning, infor-
mation processing, 
neurogenesis, neuronal 
plasticity, neurotrans-
mission 
Exercise for 30 minutes, 3 times a 
week, at least. 
Cognitive stimulation Improvement of lear-
ning, memory and 
praxis, and socializa-
tion and mood 
Reading, puzzles, crosswords, figure-
recognition and problem-solving 
games, chess, Pictionary, drawing, 
bingo, etc. 
Enriched environment Regulates stress, mood, 
behavior, sleep-wake 
cycle and sensory sti-
mulation 
Comfortable, clean and ordered 
space, social and cultural activities, 
music, lightning, no loud noises, 
company, affection 
Neuro-rehabilitation Repairs neuronal mem-
branes, synaptogenesis, 
improves memory and 
learning 
Daily consumption, monitoring of 
patients. 
Treatment Helps neurotransmi-
ssion. 
Continue drug treatment as indicated 
by medical doctor. Monitor for 
potentially risky side effects. 
General health Improves restlessness, 
humor, vision and hea-
ring, sleep, etc. 
Often checkups, treatment of 
concomitant diseases, correction of 
vision and hearing problems. 
Table 4. Integral care of the AD patient 
4.1 Nutrition 
The structure and function of the brain is affected by the nutrients in our diet as up to 50% 
of carbohydrates are consumed by the brain, lipids constitute neuronal membranes and 
amino acids, vitamins and some minerals are required for neurotransmitter synthesis and 
the maintenance of cognitive functions (Lanyau-Domínguez, 2009). Therefore, a healthy diet 
becomes important not only for preventing neuronal deterioration in non-demented 
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individuals, but for the maintenance of the remaining healthy neurons in demented 
patients. For example, glucose intake in the brain requires vitamin B1, and vitamin B12 is 
necessary for myelination, this last together with vitamin B6 are involved in 
neurotransmitter synthesis, vitamin E protects neuronal membranes; iron and iodine are 
required for cellular metabolism and manganese, copper and zinc are cofactors in the 
protection against free radicals and ROS; a high consumption of mono- and polyunsaturated 
fatty acids, DHA and EPA, together with a low consumption of saturated and trans-
saturated ones, has been associated with a better cognitive functionality. 
AD patients have demonstrated to be prone to develop nutrient deficiency due to loss of 
independence, disorientation and altered eating behavior which could lead not only to an 
exacerbation of cognitive decline but to recurrent infectious diseases, anemia and an 
increase in morbidity and mortality (Finley, 1997; Morley, 1996; Franzoni et al., 1996; Riviére 
et al., 1999). 
We recommend caregivers to implement with the therapy the following diet:  
 
A. Fish or tuna fish at least twice a week.  
B. Legumes one to three times per week.  
C. Highly energetic meals including bread, pasta, rice and potatoes.  
D. Two portions of dairy products.  
E. Two portions of meat, chicken and eggs, one portion when fish is included. 
F. Five portions of fruits and vegetables. 
G. Vegetable oils. 
H. Distribute in 5 small meals per day. 
4.2 Sleep 
In AD, as in other neurological disorders, age-related sleep disorders are exacerbated by 
several factors including homeostatic alterations in the circadian rhythms, medication side 
effects, environmental factors and medical illness. The different sleep stages have a role in 
learning and memory processes as well as in neurogenesis and neuronal plasticity. 
Furthermore, it is suggested that sleep disturbances could exacerbate Aβ aggregation and 
that the optimization of sleep time may slow the progression of AD (Kang et al., 2009). 
Fluoxetine or Escitalopram in our therapy could help to modulate sleep disorders, although 
we also suggest caregivers to pay attention to the patient’s sleep-wake cycle to try to avoid 
naps during the daytime and wakefulness during the night to promote a better nighttime 
sleep. 
4.3 Physical exercise 
Exercise helps keeping our bodies healthy and that includes our brains, it increases cerebral 
blood flow by the improvement of vascular function, improves metabolism, reduces 
inflammation and regulates several brain chemicals, but it does not stop here. It has been 
suggested that exercise may also improve memory and learning, delay age-related memory 
loss, speed information processing, aid neurogenesis and synaptic plasticity, enhance the 
glutamatergic system, increase brain derived neurotrophic factor and dendritic spines and 
reduce cell death (van Praag, 2009; Cotman et al., 2007, as cited in Wollen, 2010). Therefore 
we ask the participants in our therapy program to include at least 30 minutes of exercise 3 
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times a week, this would help improve the mood of patients and facilitate cognitive 
functions. 
4.4 Cognitive stimulation 
It is crucial to stimulate the brain while following the neuro-rehabilitation therapy as we 
shall remember our ultimate purpose is to reconnect neuronal networks in order to improve 
cognition. A higher degree of education and regular reading have proven to decrease the 
risk to develop AD, thus stimulating the brain helps to keep it healthy (“use it or lose it”). 
As our therapy is designed to be accessible to our patients’ family members or professional 
caregivers, this aspect is covered with activities that are both stimulating and recreational. 
Board games and other challenging activities could help activate memory, learning, sensory, 
motor and language processes and, when performed as a group, they may also contribute to 
socialization and mood. Therefore we ask our participants to ensure that at least one hour 
per every day will be destined to activities such as reading, solving crosswords, making 
puzzles, playing picture-recognition games, pictionary, bingo, chess, etc., and that they will 
be performed in group at least 3-4 times per week. 
4.5 Environment 
Studies have shown a significant improvement of cognition by environmental enrichment in 
models of AD (Jankowsky et al., 2005). Environmental enrichment here seeks for stress 
reduction, mood improvement, behavioral management, sleep-wake cycle regulation and 
sensory stimulation. In this aspect it is important to enrich the environment where our 
patients live within not only by social and recreating activities as we mentioned before, but 
by making them feel comfortable physically and emotionally. We ask our participants to 
create a harmonious, quiet and familial environment with an adequate lighting, music, 
order and affection. Social and cultural activities are also suggested. 
4.6 Rehabilitation 
The neuro-rehabilitation therapy should be followed as indicated. For it could take some 
time to show an improvement, maintenance and patience are needed. As we previously 
reported (Aranda-Abreu et al., 2011), we observed good outcomes with patients followed up 
to one year after the incorporation of our therapy to their AD treatment and thus we ask for 
our patients’ family members to be patient and follow the instructions to ensure the best 
possible response to the therapy. We also promote preventive precautions between patients’ 
family members, caregivers and between people above 50 years old because we believe 
prevention is currently the best weapon we could use to fight the increasing prevalence of 
AD and other age-related diseases.  
4.7 Treatment 
For all our participants that have already been diagnosed with AD by the time of initiation 
of the therapy, we recommend their relatives not to discard the drug treatment previously 
prescribed by the physician; the neuro-rehabilitation therapy should help these drugs to 
work more properly when combined. It is important to understand that these drugs do 
work and provide some benefits for AD patients, but their effect decreases as 
neurodegeneration continues; when neuronal membranes are repaired and synapses re-
established these drugs should exacerbate the positive effects of the neuro-rehabilitation 
therapy. 
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4.8 General health care 
Our recommendation to provide the best health care is to visit the physician with certain 
frequency to make sure concomitant diseases, drug side effects and possible limiting organic 
conditions are attended adequately. Comorbidity could speed up the rate of cognitive 
decline and discomfort due to physical or psychological illness might exacerbate behavioral 
and mood changes. Health care must be multidisciplinary in order to attend the whole 
range of the patients’ needs. 
5. Conclusion 
Alzheimer’s is a complex disease due to the presence of diverse pathological processes, it 
does not only involve plaque and tangle formation but inflammation, immune response, 
mitochondrial dysfunction, altered membrane traffic and positioning of molecules and a 
whole series of mechanisms leading to neuronal degeneration and death. Because of this 
diversity of events drug treatments remain scarcely effective which highlights the need for 
therapeutic strategies seeking for an integral care of every aspect of the patient’s life. In 
attendance to this need, our group has proposed a neuro-rehabilitation therapy based 
mostly on natural products for the repair of neuronal membranes and the formation of new 
synapses in order to re-establish communication and cognitive processes. This therapy 
involves a change in the patient’s lifestyle that would enhance the positive effects and 
provide a better quality of life for both patients and their families.  
Our overall purpose is to identify a fingerprint of the disease detectable in an accessible 
sample and test its ability to proportion a suitable tool for an early diagnosis of AD, as we 
offer a choice for the prevention and treatment of the disease. Our work is not quite done 
yet and our efforts to improve the quality of life for people suffering from AD will continue. 
There is still a long way to go until the day research finds a cure for AD; meanwhile, 
alternative diagnostic and therapeutic approaches are being developed by a number of 
groups around the globe to offer actual and long lasting improvements in patients’ 
cognition. Results have been promising so far and we hope in a future not so far the general 
population could find access to these approaches, though preventive strategies should be 
promoted especially for those individuals with a presumed higher risk to develop AD. 
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